Intellia Therapeutics, Inc.
0JBU.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.83B
Close$
Share Statistics
| Market cap | $1.83 Billion |
|---|---|
| Enterprise Value | $1.79 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.81 |
| Beta | 1.71 |
| Outstanding Shares | 133,479,999 |
Return
| Return on Equity | -54.96% |
|---|---|
| Return on Assets | -46.66% |
| Return on Invested Capital | -25.24% |
Valuation & Multiples
| P/E Ratio | -3.89 |
|---|---|
| PEG | -73.22 |
| Price to Sales | -11.97 |
| Price to Book Ratio | 2.39 |
| Enterprise Value to Revenue | -219.65 |
| Enterprise Value to EBIT | -9.14 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.80
Average shareholder expectationRevenue Estimate
$12.98 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.80
Average shareholder expectationRevenue Estimate
$9.74 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Intellia Therapeutics Inc
211 employees
CEO: John Leonard Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron. Intellia Th...